SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D.C. 20549


                           ---------------------------


                                    FORM 8-K


                                 CURRENT REPORT
                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934



Date of Report                                March 3, 2003
(Date of earliest event reported)             ----------------------------------

                           MedicaLogic/Medscape, Inc.
               (Exact name of registrant as specified in charter)


       Oregon                  000-28285           93-0890696
- --------------------------------------------------------------------------------

   (State or other     (Commission file         (IRS employer
   jurisdiction              number)            identification no.)
   of incorporation)

                           20540 NW Evergreen Parkway
                             Hillsboro, Oregon 97124
- --------------------------------------------------------------------------------
                    (Address of principal executive offices)


Registrant's telephone number,               (503) 531-7000
including area code                          -----------------------------------

                                 Not applicable
- --------------------------------------------------------------------------------
          (Former name or former address, if changed since last report)





     Item 3. Bankruptcy or Receivership

     On January 24, 2002,  MedicaLogic/Medscape,  Inc. (the  "Company")  and its
five United  States  subsidiaries  filed a  voluntary  petition  for  bankruptcy
protection  (collectively,  the "Bankruptcy Cases") under Chapter 11 of the U.S.
Bankruptcy  Code (the  "Code") in the  United  States  Bankruptcy  Court for the
District  of  Delaware  (the  "Bankruptcy  Court").  The  Bankruptcy  Cases were
assigned to the Honorable Judge Peter J. Walsh and are jointly  administered and
coordinated  under Case Numbers 02 - 10253 (PJW)  through 02 - 10258  (PJW).  In
addition  to  the  Company,  the  filing  entities  were  MSCP  Holdings,  Inc.,
MedicaLogic  Enterprises,  Inc., MedicaLogic  Pennsylvania,  LLC, MedicaLogic of
Texas, Inc. and MedicaLogic  Texas, L.P.  (collectively,  with the Company,  the
"Debtors").

     On November 22, 2002,  the Debtors  filed a Joint Plan of  Liquidation  and
related  Disclosure  Statement in the Bankruptcy  Court pursuant to the Code. On
December 20, 2003,  the Debtors filed a First Amended Joint Plan of  Liquidation
(the "Plan") and related First Amended  Disclosure  Statement  (the  "Disclosure
Statement"). The Court confirmed the Plan on March 3, 2003. The Plan and related
Disclosure Statement are attached hereto as Exhibit 2.1.

     As described more fully in the Plan and Disclosure  Statement,  the Debtors
currently  have no  business  operations,  and will not  initiate  or resume any
business  operations  in the  future.  Therefore,  the  Plan  provides  for  the
distribution of the Debtors'  estates,  which consist primarily of proceeds from
the sale of  substantially  all of their  assets to  certain  third  parties  as
previously  disclosed and described by the Debtors on Form 8-K, dated August 29,
2001,  Form 8-K,  dated January 10, 2002, and Form 8-K, dated April 9, 2002. The
proceeds  will be  distributed  through a  liquidating  trust (the  "Trust")  to
creditors and equity  interest  holders  pursuant to the priorities set forth in
the Code, as described more fully in the Plan and Disclosure Statement. The Plan
provides that, with respect to  distributions to holders of the Company's common
stock,  only holders of record as of December 20, 2002 that hold allowed  equity
interests are entitled to distributions under the Plan. On the effective date of
the Plan, the Trust shall be  established  and shall acquire all of the Debtors'
assets (the "Trust  Property") and assume all of the Debtors'  liabilities.  The
Trust Property will be distributed in accordance with the provisions of the Plan
and the Trust Agreement,  a copy of which is attached hereto as Exhibit 99.1, as
promptly and  efficiently as is practicable.  The foregoing  summary of the Plan
does not purport to be complete and is qualified in its entirety by reference to
the Plan, which is incorporated herein by reference.

     As of March 17,  2003,  the Company had  54,333,267  shares of common stock
outstanding and 5,500,000  shares of Series 1 convertible  redeemable  preferred
stock. There are no shares reserved for future issuance.

     For  information  relating to the assets and  liabilities  of the  Company,
please refer to the Plan and Disclosure Statement attached hereto as Exhibit 2.1
and the Debtors'  consolidating  balance sheets as of January 31, 2003, as filed
with the  Bankruptcy  Court in the Debtors'  monthly  operating  reports for the
filing period January 1, 2003 through January 31, 2003, which is attached hereto
as Exhibit 99.2.



     Item 7. Financial Statements and Exhibits.

     (c) Exhibits

================================================================================
Exhibit No.         Description
================================================================================
   2.1              First Amended Joint Plan of Liquidation and related
                    First Amended Disclosure Statement
================================================================================
  99.1              Trust Agreement, between the Debtors and Walker, Truesdell,
                    Radick & Assoc., as trustee
================================================================================
  99.2              Consolidating balance sheets of the Debtors as of
                    January 31, 2003, as filed with the Bankruptcy Court
                    in the Debtors' monthly operating reports for the
                    filing period January 1, 2003 through January 31, 2003
================================================================================






                                    SIGNATURE

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
Company  has  duly  caused  this  report  to be  signed  on  its  behalf  by the
undersigned hereunto duly authorized.

Date:  March 18, 2003



                                    MEDICALOGIC/MEDSCAPE, INC.


                                    By: /s/ Adele Kittredge Murray
                                        ----------------------------------------
                                        Name:  Adele Kittredge Murray
                                        Title: Chief Executive Officer
                                               and President







                                  EXHIBIT INDEX
================================================================================
   2.1              First Amended Joint Plan of Liquidation and related
                    First Amended Disclosure Statement
================================================================================
  99.1              Trust Agreement, between the Debtors and Walker, Truesdell,
                    Radick & Assoc., as trustee
================================================================================
  99.2              Consolidating balance sheets of the Debtors as of
                    January 31, 2003, as filed with the Bankruptcy Court
                    in the Debtors' monthly operating reports for the
                    filing period January 1, 2003 through January 31, 2003
================================================================================